Analyst firms · Truist Securities · PCRX
Truist Securities PCRX price target and rating history
Pacira BioSciences Inc. (PCRX) · Health Care
Truist Securities rates Pacira BioSciences Inc. (PCRX) Buy with a $30 price target, as of its latest action on Aug 17, 2026. It has published 4 rating actions on PCRX since August 2024, including 2 upgrades and 1 downgrade. Across 4 firms with a PCRX price target in the last 12 months, the median target is $29. Truist Securities's $30 is 3% above that.
- Current rating
- Buy
- Price target
- $30
- Median target, all firms
- $29
- Actions on PCRX
- 4
Truist Securities price target on PCRX
Every Truist Securities rating on PCRX
- Aug 17, 2026
- Jul 25, 2025
- Jan 30, 2025
- Aug 13, 2024
How other firms rate PCRX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Oppenheimer | Outperform | $32 | Sep 23, 2026 |
| Leerink Partners | Market Perform | $28 | Sep 9, 2026 |
| Truist Securities | Buy | $30 | Aug 17, 2026 |
| Barclays | Equal Weight | $27 | Dec 9, 2025 |
Questions about Truist Securities and PCRX
- What is Truist Securities's price target for PCRX?
- Truist Securities's latest stated price target for Pacira BioSciences Inc. (PCRX) is $30, from its action on Aug 17, 2026.
- What is Truist Securities's rating on PCRX?
- Truist Securities rates PCRX Buy, a bullish rating, as of Aug 17, 2026.
- When did Truist Securities last change its view on PCRX?
- On Aug 17, 2026, Truist Securities resumes coverage at Buy, price target $30.
- How does Truist Securities's PCRX target compare with other analysts?
- Across 4 firms with a PCRX price target in the last 12 months, the median target is $29. Truist Securities's $30 is 3% above that.
More PCRX rating histories
All Truist Securities ratingsPCRX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.